According to the Zhitong Finance App, Lanwei Medical (301060.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 592 million yuan, a year-on-year decrease of 22.09%. Achieved net profit of 63.5938 million yuan attributable to shareholders of listed companies. Achieve net profit of 16.3927 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss. Basic earnings per share were $0.16.

During the reporting period, the overall business environment of the industry was under pressure due to the combined impact of multiple factors of industry policies such as medical insurance fee control and procurement expansion. Closely following the country's strategic direction of strengthening primary care capabilities and promoting the development of digital pathology, the company took the initiative to shrink some of its low-profit businesses. In the first half of 2026, the company cut the low gross margin distribution business in the in vitro diagnostic product sales segment, focusing more on regional testing and pathology center business with high gross margin in the medical diagnostic service sector, so operating income declined compared to the same period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.